Literature DB >> 15042144

Clinical implications of pharmacogenomics for tardive dyskinesia.

D J Müller1, T Shinkai, V De Luca, J L Kennedy.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15042144     DOI： 10.1038/sj.tpj.6500233

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


× No keyword cloud information.
  10 in total

1.  Metoclopramide in the treatment of diabetic gastroparesis.

Authors:  Allen Lee; Braden Kuo
Journal:  Expert Rev Endocrinol Metab       Date:  2010

2.  Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence.

Authors:  Mahendra Bishnoi; Kanwaljit Chopra; Lu Rongzhu; Shrinivas K Kulkarni
Journal:  Neurotox Res       Date:  2010-11-13       Impact factor: 3.911

3.  Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

Authors:  Michel C F Shamy; Clement Zai; Vincenzo S Basile; James L Kennedy; Daniel J Müller; Mario Masellis
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-06-01

4.  Pharmacogenetics of antipsychotic treatment response and side effects.

Authors:  B Mackenzie; Rp Souza; O Likhodi; Ak Tiwari; Cc Zai; J Sturgess; Dj Müller
Journal:  Therapy       Date:  2010-03

5.  Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes.

Authors:  B K Thelma; Arun K Tiwari; Smita N Deshpande; Bernard Lerer; Vishwajit L Nimgaonkar
Journal:  Schizophr Res       Date:  2007-02-21       Impact factor: 4.939

6.  Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.

Authors:  Li Hui; Mei Han; Xu Feng Huang; Min Jie Ye; Ke Zheng; Jin Cai He; Meng Han Lv; Bao Hua Zhang; Jair C Soares; Xiang Yang Zhang
Journal:  J Neural Transm (Vienna)       Date:  2014-10-22       Impact factor: 3.575

Review 7.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

8.  Lessons from pharmacogenetics and metoclopramide: toward the right dose of the right drug for the right patient.

Authors:  Michael Camilleri; Andrea Shin
Journal:  J Clin Gastroenterol       Date:  2012-07       Impact factor: 3.062

9.  Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

Authors:  Samar S M Elsheikh; Daniel J Müller; Jennie G Pouget
Journal:  Methods Mol Biol       Date:  2022

10.  Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

Authors:  Aoi Syu; Hiroki Ishiguro; Toshiya Inada; Yasue Horiuchi; Syunsuke Tanaka; Maya Ishikawa; Makoto Arai; Masanari Itokawa; Kazuhiro Niizato; Shuji Iritani; Norio Ozaki; Makoto Takahashi; Akiyoshi Kakita; Hitoshi Takahashi; Hiroyuki Nawa; Kazuko Keino-Masu; Eri Arikawa-Hirasawa; Tadao Arinami
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.